Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy

CONTEXT: Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available. OBJECTIVES: To evaluate the effects of 8 years of rhPT...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Endocrinol Metab
Asıl Yazarlar: Tabacco, Gaia, Tay, Yu-Kwang Donovan, Cusano, Natalie E, Williams, John, Omeragic, Beatriz, Majeed, Rukhana, Almonte, Maximo Gomez, Rubin, Mishaela R, Bilezikian, John P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Endocrine Society 2019
Konular:
Clinical Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6530656/
https://ncbi.nlm.nih.gov/pubmed/30776291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02430
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller